Literature DB >> 20037279

Current status of liver diseases in Korea: liver cirrhosis.

Jeong Won Jang1.   

Abstract

Liver cirrhosis represents the final common pathway of virtually all chronic liver diseases, and is characterized by an accumulation of extracellular matrix rich in fibrillar collagens. Patients with cirrhosis are at risk of developing many potential complications. The most common complication seen in patients with liver cirrhosis is ascites, and the most lethal one is bleeding varices. Other intermediate and late stage complications include spontaneous bacterial peritonitis, hepatic encephalopathy, and hepatorenal syndrome. The mortality and morbidity attributable to liver disease in Korea have decreased continuously over the past decades, probably due to the implementation of universal vaccination and potent antiviral therapies. In addition, recent advances in the understanding of the pathophysiology of cirrhosis and in various management approaches to cirrhosis complications will contribute to the steady improvement in patient outcomes in this country. This review article outlines recent changes in etiologies and prognosis, and the advances in management of cirrhosis in Korea.

Entities:  

Mesh:

Year:  2009        PMID: 20037279     DOI: 10.3350/kjhep.2009.15.S6.S40

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  12 in total

Review 1.  Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives.

Authors:  Beom Kyung Kim; James Fung; Man-Fung Yuen; Seung Up Kim
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

2.  Inguinal hernia repair in patients with cirrhosis is not associated with increased risk of complications and recurrence.

Authors:  Heung-Kwon Oh; Hansuk Kim; Seungbum Ryoo; Eun Kyung Choe; Kyu Joo Park
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

3.  Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea.

Authors:  Hana Park; Jin Young Yoon; Kyeong Hye Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

4.  Health-related quality of life and survival in Chinese patients with chronic liver disease.

Authors:  Feng Gao; Ru Gao; Guang Li; Zhan Min Shang; Jian Yu Hao
Journal:  Health Qual Life Outcomes       Date:  2013-08-01       Impact factor: 3.186

5.  Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis.

Authors:  Pei Chuan Tsung; Soo Hyung Ryu; In Hye Cha; Hee Won Cho; Jin Nam Kim; You Sun Kim; Jeong Seop Moon
Journal:  Clin Mol Hepatol       Date:  2013-06-27

6.  Iron deficient erythropoiesis might play key role in development of anemia in cancer patients.

Authors:  Silvia Park; Chul Won Jung; Kihyun Kim; Seok Jin Kim; Won Seog Kim; Jun Ho Jang
Journal:  Oncotarget       Date:  2015-12-15

7.  Changing trends of hospitalisation of liver cirrhosis in Beijing, China.

Authors:  Xiao-Yuan Bao; Bei-Bei Xu; Kai Fang; Yan Li; Yong-Hua Hu; Guo-Pei Yu
Journal:  BMJ Open Gastroenterol       Date:  2015-08-27

8.  Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol.

Authors:  Jae Hyun Yoon; Chung Hwan Jun; Jeong Han Kim; Eileen L Yoon; Byung Seok Kim; Jeong Eun Song; Ki Tae Suk; Moon Young Kim; Seong Hee Kang
Journal:  J Korean Med Sci       Date:  2021-05-31       Impact factor: 2.153

9.  Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis.

Authors:  Honggang Zhang; Qinqin Sun; Weilin Mao; Jian Fan; Bo Ye
Journal:  Gastroenterol Res Pract       Date:  2016-02-02       Impact factor: 2.260

10.  AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis.

Authors:  Weilin Mao; Qinqin Sun; Jian Fan; Sha Lin; Bo Ye
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.